KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment: 2020-2024

Historic Asset Writedowns and Impairment for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2024 value amounting to $108,000.

  • Recursion Pharmaceuticals' Asset Writedowns and Impairment rose 5414.81% to $6.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year increase of 76.79%. This contributed to the annual value of $108,000 for FY2024, which is 90.91% down from last year.
  • As of FY2024, Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $108,000, which was down 90.91% from $1.2 million recorded in FY2023.
  • Recursion Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $2.8 million during FY2022, with a 5-year trough of $108,000 in FY2024.
  • Over the past 3 years, Recursion Pharmaceuticals' median Asset Writedowns and Impairment value was $1.2 million (recorded in 2023), while the average stood at $1.4 million.
  • Data for Recursion Pharmaceuticals' Asset Writedowns and Impairment shows a maximum YoY crashed of 90.91% (in 2024) over the last 5 years.
  • Yearly analysis of 4 years shows Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $874,000 in 2020, then reached $2.8 million in 2022, then plummeted by 57.66% to $1.2 million in 2023, then crashed by 90.91% to $108,000 in 2024.